Vericel Corp. is planning a public offering of 3,750,000 common shares to raise funds for general corporate purposes.
Leerink Partners is acting as the lead book runner while BTIG LLC is acting as a book runner for the offering.
The Cambridge, Mass.-based biopharmaceutical company intends to grant the underwriters a 30-day option to buy up to an additional 562,500 common shares.
